FY2024 EPS Estimates for Eyenovia Lifted by HC Wainwright

Eyenovia, Inc. (NASDAQ:EYEN) – HC Wainwright boosted their FY2024 earnings estimates for shares of Eyenovia in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.51) for the year, up from their previous forecast of ($0.67). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.56 EPS.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the prior year, the firm earned ($0.18) EPS.

A number of other equities research analysts have also recently commented on the stock. Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a research note on Friday. William Blair reissued a “market perform” rating on shares of Eyenovia in a research note on Friday.

Eyenovia Stock Down 70.0 %

EYEN stock opened at $0.10 on Friday. The business’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.71. The stock has a market cap of $6.53 million, a P/E ratio of -0.14 and a beta of 1.75. The company has a quick ratio of 0.27, a current ratio of 0.74 and a debt-to-equity ratio of 0.58. Eyenovia has a twelve month low of $0.09 and a twelve month high of $2.57.

Hedge Funds Weigh In On Eyenovia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in Eyenovia in the second quarter worth $3,601,000. Vanguard Group Inc. grew its stake in shares of Eyenovia by 25.2% in the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after buying an additional 360,924 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Eyenovia by 36.6% in the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after buying an additional 149,471 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Eyenovia by 1,444.4% during the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares in the last quarter. Finally, SkyView Investment Advisors LLC bought a new position in shares of Eyenovia in the 2nd quarter valued at about $87,000. 25.84% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Michael M. Rowe acquired 50,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This trade represents a 151.85 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 7.10% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.